Fundraising FoxAadi Bioscience
NASDAQ: WHWKMorristown, US · Delaware corporation · 9 known investors
Find your way into Aadi Bioscience
Sign up to see every warm intro you have to Aadi Bioscience
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aadi Bioscience team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition. It operates in the biotechnology and pharmaceutical sector.
Founders & leadership
BB
Bryan BallExecutive
DL
Dave LennonPresident and CEO2023–2025Dave Lennon is an executive officer and director at Aadi Bioscience, a biotechnology company developing mTOR-targeted therapies using albumin-bound nanoparticle technology and genomic profiling.
DD
David DornanExecutive
JM
James MurphyExecutive
SP
Stephen PakolaExecutive
KG
Kevin G. PetersExecutive
MD
Margaret DuganChief Medical Officer
ND
Neil DesaiNamed on SEC filing
JG
Joseph GardnerNamed on SEC filing
Board
BZ
Baiteng ZhaoBoard director
CC
Caley CasteleinBoard director
Investors · 9
Ally Bridge Grouplisted by Ally Bridge GroupNew York
How we know: Ally Bridge Group's portfolio page · Not right? Tell us
Decheng Capitallisted by Decheng CapitalMenlo Park
How we know: Decheng Capital's portfolio page · labusinessjournal.com · the VCSheet dataset · Not right? Tell us
Also in the syndicate · 4
Celgene Corp.Helsinn Investment FundHermed CapitalleadStar Summit Ventures
Funding
SEC filings, press & company announcements$451.8M disclosed across 5 of 7 rounds · 1900–2025
- Undisclosed amountseries AMay 2018
Hermed Capital (lead), Celgene Corp., Decheng Capital, Helsinn Investment Fund, Star Summit Ventures, Vivo Capital
Source ↗
▶$100MraisedMar 2025 · 17 investors · BiotechnologyRule 506(b)
▶$100MraisedMar 2025 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Baiteng ZhaoDirector
- Scott GiacobelloExecutive Officer
- Caley CasteleinDirector
- Richard MarounDirector
- Bryan BallExecutive Officer
- Behzad AghazadehDirector
- Emma ReeveDirector
- Dave LennonExecutive Officer, Director
- David DornanExecutive Officer
- Mohammad HirmandDirector
- Karin HehenbergerDirector
- Neil DesaiDirector
- Anupam DalalDirector
- Offering amount
- $100M
- Amount sold
- $100M
- Sales commissions
- $4.3M
- Placement agents
- Jefferies LLC
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$72.5MraisedOct 2022 · 13 investors · BiotechnologyRule 506(b)
▶$72.5MraisedOct 2022 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Karin HehenbergerDirector
- Brendan DelaneyExecutive Officer
- Scott GiacobelloExecutive Officer
- Caley CasteleinDirector
- Richard MarounDirector
- Loretta ItriExecutive Officer
- Neil DesaiExecutive Officer, Director
- Anupam DalalDirector
- Emma ReeveDirector
- Behzad AghazadehDirector
- Offering amount
- $72.5M
- Amount sold
- $72.5M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$155MraisedSep 2021 · 31 investors · BiotechnologyRule 506(b)
▶$155MraisedSep 2021 · 31 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Caley CasteleinDirector
- Neil DesaiExecutive Officer, Director
- Anupam DalalDirector
- Emma ReeveDirector
- Richard MarounDirector
- Lance ThibaultExecutive Officer
- Karin HenebergerDirector
- Offering amount
- $155M
- Amount sold
- $155M
- Finders' fees
- $9.3M
- Placement agents
- Cowen and Company LLC, Jefferies LLC, Piper Sandler & Co.
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$82.5MraisedSep 2021 · 15 investors · BiotechnologyRule 506(b)
▶$82.5MraisedSep 2021 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anupam DalalDirector
- Neil DesaiExecutive Officer, Director
- Karin HenebergerDirector
- Richard MarounDirector
- Emma ReeveDirector
- Caley CasteleinDirector
- Lance ThibaultExecutive Officer
- Offering amount
- $82.5M
- Amount sold
- $82.5M
- Sales commissions
- $2M
- Placement agents
- Perella Weinberg Partners LP, Piper Sandler & Co.
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$41.8MraisedMar 2017 · 264 investors · BiotechnologyRule 506(b)
▶$41.8MraisedMar 2017 · 264 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Muneer SatterDirector
- Steven PrelackDirector
- Anupam DalalDirector
- Joseph GardnerExecutive Officer, Director
- James MurphyExecutive Officer
- Stephen PakolaExecutive Officer
- Pravin DugelDirector
- Chau KhuongDirector
- Kevin G. PetersExecutive Officer
- Paul M. WeissDirector
- Caley CasteleinDirector
- Offering amount
- $41.8M
- Amount sold
- $41.8M
- Sales commissions
- $4.2M
- Placement agents
- Katalyst Securities LLC, National Securities Corporation, Raymond James & Associates, Inc.
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$135.2Mvaluation at IPOJun 2017 · $5.00/share · S-1/A
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 1
Companies working in the same space as Aadi Bioscience.
Frequently asked questions
- What does Aadi Bioscience do?
- Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition. It operates in the biotechnology and pharmaceutical sector.
- Who are Aadi Bioscience's investors?
- Aadi Bioscience's investors include 3B Future Health Fund, Ally Bridge Group, Decheng Capital, Vivo Capital, OrbiMed.
- How much funding has Aadi Bioscience raised?
- Aadi Bioscience has disclosed $451.8M raised across 5 of its 7 known rounds.
- Where is Aadi Bioscience headquartered?
- Aadi Bioscience is headquartered in Morristown, US.